Modification of human papillomavirus minor capsid protein L2 by sumoylation

Journal of Virology

Volumn 84, Issue 21, 2010, Pages 11585-11589

  Marušič, Martina Bergant ^a,b   Mencin, Nina ^a   Ličen, Mia ^a   Banks, Lawrence ^b   Šterlinko Grm, Helena ^a  

^a UNIVERSITY OF NOVA GORICA   (Slovenia)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L2; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UNCLASSIFIED DRUG; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; LYSINE; ONCOPROTEIN; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; SUMOYLATION; WART VIRUS; WESTERN BLOTTING; CHEMISTRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; METABOLISM;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

CAPSID PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYSINE; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; PROTEIN STABILITY; SUMO-1 PROTEIN;

EID: 77957959661     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01269-10     Document Type: Article

References (32)

1. Anckar, J., and L. Sistonen. 2007. SUMO: getting it on. Biochem. Soc. Trans. 35:1409-1413.
2. Bies, J., J. Markus, and L. Wolff. 2002. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J. Biol. Chem. 15:8999-9009.
3. Bischof, O., K. Schwamborn, N. Martin, A. Werner, C. Sustmann, R. Grosschedl, and A. Dejean. 2006. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 23:783-794. (Pubitemid 43912473)
4. Boggio, R., and S. Chiocca. 2005. Gam1 and the SUMO pathway. Cell Cycle 4:533-535.
5. Boggio, R., and S. Chiocca. 2006. Viruses and sumoylation: recent highlights. Curr. Opin. Microbiol. 9:430-436.
6. Bossis, I., R. B. Roden, R. Gambhira, R. Yang, M. Tagaya, P. M. Howley, and P. I. Meneses. 2005. Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J. Virol. 79:6723-6731.
7. Desterro, J. M., M. S. Rodriguez, and R. T. Hay. 1998. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell 2:233-239.
8. Deyrieux, A. F., and V. G. Wilson. 2009. Viral interplay with the host sumoylation system, p. 315-329. In V. G. Wilson (ed.), SUMO regulation of cellular processes. Springer, Dordrecht, Netherlands.
9. Deyrieux, A. F., G. Rosas-Acosta, M. A. Ozbun, and V. G. Wilson. 2007. Sumoylation dynamics during keratinocyte differentiation. J. Cell Sci. 1:125-136.
10. Finnen, R. L., K. D. Erickson, X. S. Chen, and R. L. Garcea. 2003. Interaction between papillomavirus L1 and L2 capsid proteins. J. Virol. 77:4818-4826.
11. Hebner, C. M., and L. A. Laimins. 2006. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol. 16:83-97.
12. Heun, P. 2007. SUMOrganization of the nucleus. Curr. Opin. Cell Biol. 19:350-355.
13. Holmgren, S. C., N. A. Patterson, M. A. Ozbun, and P. F. Lambert. 2005. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J. Virol. 79:3938-3948.
14. Ledl, A., D. Schmidt, and S. Müller. 2005. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 26:3810-3818. (Pubitemid 40826879)
15. Okoye, A., P. Cordano, E. R. Taylor, I. M. Morgan, R. Everett, and M. S. Campo. 2005. Human papillomavirus 16 L2 inhibits the transcriptional activation function, but not the DNA replication function, of HPV-16 E2. Virus Res. 108:1-14.
16. Pereira, R., I. I. Hitzeroth, and E. P. Rybicki. 2009. Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch. Virol. 154:187-197.
17. Rangasamy, D., K. Woytek, S. A. Khan, and V. G. Wilson. 2000. SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation. J. Biol. Chem. 275:37999-38004.
18. Richards, R. M., D. R. Lowy, J. T. Schiller, and P. M. Day. 2006. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. U. S. A. 103:1522-1527.
19. Rosas-Acosta, G., M. A. Langereis, A. Deyrieux, and V. G. Wilson. 2005. Proteins of the PIAS family enhance the sumoylation of the papillomavirus E1 protein. Virology 331:190-203.
20. Rosas-Acosta, G., W. K. Russell, A. Deyrieux, D. H. Russell, and V. G. Wilson. 2005. A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell. Proteomics 4:56-72.
21. Sapp, M., and M. Bienkowska-Haba. 2009. Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J. 276:7206-7216.
22. Sun, X. Y., I. Frazer, M. Müller, L. Gissmann, and J. Zhou. 1995. Sequences required for the nuclear targeting and accumulation of human papillomavirus type 6B L2 protein. Virology 213:321-327.
23. Tomaić, V., D. Pim, and L. Banks. 2009. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 393:7-10.
24. Vertegaal, A. C., J. S. Andersen, S. C. Ogg, R. T. Hay, M. Mann, and A. I. Lamond. 2006. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell. Proteomics 5:2298-2310.
25. Wei, F., H. R. Schöler, and M. L. Atchison. 2007. Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J. Biol. Chem. 282:21551-21560.
26. Wu, Y. C., A. A. Roark, X. L. Bian, and V. G. Wilson. 2008. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology 378:329-338.
27. Wu, Y. C., A. F. Deyrieux, and V. G. Wilson. 2007. Papillomaviruses and the host SUMOylation system. Biochem. Soc. Trans. 35:1433-1435.
28. Wu, Y. C., X. L. Bian, P. R. Heaton, A. F. Deyrieux, and V. G. Wilson. 2009. Host cell sumoylation level influences papillomavirus E2 protein stability. Virology 387:176-183.
29. Yang, W., and W. Paschen. 2009. Gene expression and cell growth are modified by silencing SUMO2 and SUMO3 expression. Biochem. Biophys. Res. Commun. 382:215-218.
30. Zhang, X. D., J. Goeres, H. Zhang, T. J. Yen, A. C. Porter, and M. J. Matunis. 2008. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol. Cell 29:729-741.
31. Zhao, J. 2007. Sumoylation regulates diverse biological processes. Cell. Mol. Life Sci. 64:3017-3033.
32. Zhou, J., X. Y. Sun, K. Louis, and I. H. Frazer. 1994. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J. Virol. 68:619-625.